CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
The U.S. birth rate declined by 1% in 2025, according to preliminary data released by the Centers for Disease Control and Prevention. The cesarean delivery…
Headline
The AHA and Epic are launching the Safer Births PPH Collaborative, a seven-month initiative designed to support hospitals in reducing postpartum hemorrhage…
Headline
The AHA Feb. 17 submitted a comment letter responding to the Centers for Medicare & Medicaid Services’ proposed rule that would prohibit hospitals…
Headline
A new blog shares key takeaways from the AHA’s Better Health for Mothers and Babies webinar series, where hospitals share how they are putting the initiative’s…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 30 that it will no longer require states to report measures reflecting the immunization status…
Headline
The Centers for Disease Control and Prevention Jan. 5 updated the childhood vaccine schedule, recommending three categories of vaccines. The first category…